CA2951768C - Stabilized desmopressin - Google Patents

Stabilized desmopressin Download PDF

Info

Publication number
CA2951768C
CA2951768C CA2951768A CA2951768A CA2951768C CA 2951768 C CA2951768 C CA 2951768C CA 2951768 A CA2951768 A CA 2951768A CA 2951768 A CA2951768 A CA 2951768A CA 2951768 C CA2951768 C CA 2951768C
Authority
CA
Canada
Prior art keywords
desmopressin
pharmaceutical composition
gum
acceptable salt
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2951768A
Other languages
English (en)
French (fr)
Other versions
CA2951768A1 (en
Inventor
Bong Sang Lee
Su-Jun Park
Jiyeong HAN
Myeongcheol KIL
Min Seop Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferring BV
Original Assignee
Ferring BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53510836&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2951768(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring BV filed Critical Ferring BV
Publication of CA2951768A1 publication Critical patent/CA2951768A1/en
Application granted granted Critical
Publication of CA2951768C publication Critical patent/CA2951768C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2951768A 2014-06-16 2015-06-15 Stabilized desmopressin Active CA2951768C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020140073067 2014-06-16
KR1020140073067A KR20150144209A (ko) 2014-06-16 2014-06-16 안정화된 데스모프레신 또는 이의 약학적으로 허용가능한 염을 함유 약학 조성물
PCT/EP2015/063347 WO2015193246A1 (en) 2014-06-16 2015-06-15 Stabilized desmopressin

Publications (2)

Publication Number Publication Date
CA2951768A1 CA2951768A1 (en) 2015-12-23
CA2951768C true CA2951768C (en) 2022-08-30

Family

ID=53510836

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2951768A Active CA2951768C (en) 2014-06-16 2015-06-15 Stabilized desmopressin

Country Status (33)

Country Link
US (1) US20170128521A1 (cg-RX-API-DMAC10.html)
EP (1) EP3154516B1 (cg-RX-API-DMAC10.html)
JP (1) JP6615130B2 (cg-RX-API-DMAC10.html)
KR (2) KR20150144209A (cg-RX-API-DMAC10.html)
CN (1) CN106456706B (cg-RX-API-DMAC10.html)
AR (1) AR100850A1 (cg-RX-API-DMAC10.html)
AU (1) AU2015276247C1 (cg-RX-API-DMAC10.html)
CA (1) CA2951768C (cg-RX-API-DMAC10.html)
CL (1) CL2016003219A1 (cg-RX-API-DMAC10.html)
CO (1) CO2017000354A2 (cg-RX-API-DMAC10.html)
DK (1) DK3154516T3 (cg-RX-API-DMAC10.html)
EA (1) EA032834B1 (cg-RX-API-DMAC10.html)
ES (1) ES2751600T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20191746T1 (cg-RX-API-DMAC10.html)
HU (1) HUE045395T2 (cg-RX-API-DMAC10.html)
IL (1) IL249538A0 (cg-RX-API-DMAC10.html)
JO (1) JO3500B1 (cg-RX-API-DMAC10.html)
LT (1) LT3154516T (cg-RX-API-DMAC10.html)
MX (1) MX374540B (cg-RX-API-DMAC10.html)
MY (1) MY182781A (cg-RX-API-DMAC10.html)
NZ (1) NZ727388A (cg-RX-API-DMAC10.html)
PH (1) PH12016502527B1 (cg-RX-API-DMAC10.html)
PL (1) PL3154516T3 (cg-RX-API-DMAC10.html)
PT (1) PT3154516T (cg-RX-API-DMAC10.html)
RS (1) RS59449B1 (cg-RX-API-DMAC10.html)
SA (1) SA516380492B1 (cg-RX-API-DMAC10.html)
SG (2) SG10201811139UA (cg-RX-API-DMAC10.html)
SI (1) SI3154516T1 (cg-RX-API-DMAC10.html)
TN (1) TN2016000561A1 (cg-RX-API-DMAC10.html)
TW (1) TWI670070B (cg-RX-API-DMAC10.html)
UA (1) UA119776C2 (cg-RX-API-DMAC10.html)
WO (1) WO2015193246A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201608020B (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114432424B (zh) * 2021-12-27 2023-06-27 南通联亚药业股份有限公司 一种稳定的铝塑包装去氨加压素片剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE60941B1 (en) * 1986-07-10 1994-09-07 Elan Transdermal Ltd Transdermal drug delivery device
GB0210397D0 (en) * 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
DE60307082D1 (de) * 2002-05-07 2006-09-07 Ferring Bv In der mundhöhle dispergierbare phamarzeutische zusammensetzung mit desmopressin
WO2007083323A2 (en) * 2006-01-23 2007-07-26 Panacea Biotec Limited. Modified release oral dosage form comprising desmopressin
CN100463674C (zh) * 2006-12-22 2009-02-25 江苏奥赛康药业有限公司 一种氯雷他定口腔速溶膜及其制备方法
US20150306170A1 (en) * 2012-11-21 2015-10-29 Ferring B.V. Composition for immediate and extended release
TW201422254A (zh) * 2012-11-21 2014-06-16 Ferring Bv 用於速釋及延釋的組成物

Also Published As

Publication number Publication date
BR112016029417A2 (pt) 2017-08-22
HRP20191746T1 (hr) 2019-12-27
JP2017523955A (ja) 2017-08-24
WO2015193246A1 (en) 2015-12-23
US20170128521A1 (en) 2017-05-11
KR20170020450A (ko) 2017-02-22
RS59449B1 (sr) 2019-11-29
DK3154516T3 (da) 2019-09-23
TWI670070B (zh) 2019-09-01
AU2015276247B2 (en) 2019-09-12
EA201692556A1 (ru) 2017-04-28
PH12016502527A1 (en) 2017-04-10
NZ727388A (en) 2021-07-30
PL3154516T3 (pl) 2020-08-10
CN106456706B (zh) 2020-07-14
AR100850A1 (es) 2016-11-02
SA516380492B1 (ar) 2021-02-03
TN2016000561A1 (en) 2018-04-04
JO3500B1 (ar) 2020-07-05
KR20150144209A (ko) 2015-12-24
ZA201608020B (en) 2020-05-27
JP6615130B2 (ja) 2019-12-04
KR102360656B1 (ko) 2022-02-09
CA2951768A1 (en) 2015-12-23
EP3154516B1 (en) 2019-09-04
SI3154516T1 (sl) 2019-11-29
HUE045395T2 (hu) 2019-12-30
CL2016003219A1 (es) 2017-06-30
MX374540B (es) 2025-03-06
PH12016502527B1 (en) 2017-04-10
SG10201811139UA (en) 2019-01-30
ES2751600T3 (es) 2020-04-01
UA119776C2 (uk) 2019-08-12
IL249538A0 (en) 2017-02-28
MY182781A (en) 2021-02-05
CO2017000354A2 (es) 2017-03-31
EP3154516A1 (en) 2017-04-19
CN106456706A (zh) 2017-02-22
SG11201609374YA (en) 2017-01-27
AU2015276247C1 (en) 2020-02-06
MX2016016635A (es) 2017-06-06
LT3154516T (lt) 2019-10-25
EA032834B1 (ru) 2019-07-31
PT3154516T (pt) 2019-12-05
BR112016029417A8 (pt) 2021-06-29
TW201605464A (zh) 2016-02-16
AU2015276247A1 (en) 2017-02-02

Similar Documents

Publication Publication Date Title
KR101546596B1 (ko) 베포타스틴 조성물
CN100374112C (zh) 罗替戈汀鼻内组合物
JP6084161B2 (ja) 7−[4−(4−ベンゾ[b]チオフェン−4−イル−ピペラジン−1−イル)ブトキシ]−1H−キノリン−2−オン又はその塩を含む錠剤
AU2014221630B2 (en) Suspension for oral administration comprising amorphous tolvaptan
CN105395528A (zh) 依匹哌唑口腔速溶膜
US10583087B2 (en) Pharmaceutical composition for oral administration
CN102784382A (zh) 一种阿加曲班药物组合物及其制备方法和应用
AU2015276247B2 (en) Stabilized desmopressin
CN108024952A (zh) 在治疗发作中用于口颊施用以获得快速起效的咪达唑仑组合物
TW201609184A (zh) 包含蒙特魯卡斯特(montelukast)或其藥學上可接受之鹽類的液體調配物及其製備方法
US20210369624A1 (en) Solid oral dosage form having excellent dissolution properties
CN102641240B (zh) 一种苦柯胺b盐注射剂及其制备方法
CN117159446A (zh) 一种盐酸氨溴索口服凝胶制剂、制法及其应用
HK1235295A1 (en) Stabilized desmopressin
HK1235295B (en) Stabilized desmopressin
BR112016029417B1 (pt) Composição farmacêutica na forma de uma película de desintegração oral, seu método de preparação, e uso de gomas para aumentar sua estabilidade
WO2013062497A1 (en) Liquid pharmaceutical formulations
CN107669642A (zh) 一种右旋艾普拉唑钠冻干粉针剂
TW201311266A (zh) 與埃紮斯特之賦形劑相容性
WO2025108313A1 (zh) 包含egfr抑制剂的药物组合物
CN108853033A (zh) 一种喹硫平药物制剂
HK1216620B (en) Suspension for oral administration comprising amorphous tolvaptan

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200521

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250603

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250603

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260804